Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant [Phase 1]
Phase 1 trial evaluating emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil to prevent graft-versus-host…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants [Phase 2]
Phase 2 clinical trial update describing the addition of itacitinib to cyclophosphamide and tacrolimus for preventing graft-versus-host dise…
-
CLINICAL_TRIALS trial_result · 2025-05-25Clinical Trial Update: Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza [Phase 1]
Phase 1 blinded cross-over bioequivalence trial comparing Luitpold azacitidine with Vidaza has completed, with results posted.
-
CLINICAL_TRIALS withdrawal · 2025-05-25Clinical Trial Update: Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor [Phase 1]
A Phase 1 study evaluating multi-antigen specific CD8+ T cells with decitabine and lymphodepleting chemotherapy for relapsed or refractory a…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A phase 1/2 study of DS-1594b with or without azacitidine, venetoclax, or mini-HCVD in relapsed or refractory acute myeloid leukemia or acut…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS [Phase 1]
A Phase 1 study from Novartis evaluating PDR001 and MBG453 with decitabine in acute myeloid leukemia or high-risk myelodysplastic syndromes …
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS [Phase 2]
This clinical trial update describes a Phase 2 study evaluating palliative care oncology in adults with relapsed, refractory, or high-risk a…
-
CLINICAL_TRIALS research · 2025-05-11Clinical Trial Update: ATG Plus PTCy vs ATG for CGVHD Prophylaxis [Phase 2]
Phase 2 trial comparing ATG plus post-transplant cyclophosphamide versus ATG for prophylaxis of chronic graft-versus-host disease in patient…
-
CLINICAL_TRIALS trial_result · 2025-04-29Clinical Trial Update: IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation [EARLY_Phase 1]
A Phase 1 trial evaluating interferon-gamma (IFN-γ) for relapsed myelodysplastic syndrome and acute myeloid leukemia after allogeneic stem c…
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating a three-drug combination of azacitidine, venetoclax, and trametinib for relapsed or refractory acute myeloid leukem…
-
CLINICAL_TRIALS withdrawal · 2025-04-22Clinical Trial Update: Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction [Phase 2]
Phase 2 frontline trial evaluating cladribine/low-dose cytarabine alternating with decitabine versus hypomethylating agents plus venetoclax …
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial [Phase 2]
Phase 2 trial evaluating fecal microbiota transplantation before allogeneic stem cell transplant; recruitment is ongoing across multiple hem…
-
CLINICAL_TRIALS trial_result · 2025-04-15Clinical Trial Update: AZA+Lus VS AZA Monotherapy in HR-MDS [Phase 3]
Phase 3 trial comparing azacitidine plus Lus versus azacitidine monotherapy in higher-risk myelodysplastic syndrome; the study is not yet re…
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) [Phase 1]
Phase 1 clinical trial assessing a preventive therapy to reduce graft-versus-host disease in participants with hematologic malignancies unde…
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [Phase 1]
Phase 1 study of Veliparib with Topotecan, with or without Carboplatin, in relapsed or refractory acute leukemias, high-risk myelodysplastic…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation [Phase 2]
Phase 2 trial evaluating olaparib for relapsed/refractory IDH-mutated acute myeloid leukemia or myelodysplastic syndrome; results posted 202…
-
CLINICAL_TRIALS research · 2025-03-28Clinical Trial Update: Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients [Phase 2]
Phase 2 clinical trial evaluating selinexor in combination with azacitidine for high-risk myeloid neoplasms, currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS [Phase 1]
Phase 1, open-label study of intravenous GSK3745417 in relapsed/refractory myeloid malignancies (AML and high-risk myelodysplastic syndrome)…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
This Phase 2 trial investigates reduced-intensity chemotherapy and radiation therapy before donor stem cell transplantation for various hema…
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies [Phase 1]
Phase 1 study of XS-04 in relapsed or refractory hematologic malignancies, including B-cell lymphoma, acute myeloid leukemia, and myelodyspl…
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: Blood Samples to Identify Biomarkers of Busulfan
A terminated clinical trial at Fred Hutchinson Cancer Center investigated using blood samples to identify biomarkers of busulfan exposure. T…
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome [Phase 1, Phase 2]
Akeso's AK117 (anti-CD47) is in a Phase 1/2 clinical trial for myelodysplastic syndrome and the study is currently active but not recruiting…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Phase 1]
Phase 1 study evaluating ruxolitinib in patients with low or intermediate-1 risk myelodysplastic syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-21Clinical Trial Update: APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies [Phase 1]
Phase 1 study evaluating APR-246 in combination with venetoclax and azacitidine for TP53-mutant myeloid malignancies has completed and poste…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes [Phase 2]
A Phase 2 study evaluating AK117 in combination with azacitidine for higher-risk myelodysplastic syndromes is currently recruiting.